HighVista Strategies’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.86M Sell
32,480
-18,645
-36% -$1.94M 0.75% 39
2026
Q2
$4.98M Buy
51,125
+15,538
+44% +$1.36M 1.14% 25
2026
Q1
$2.99M Sell
35,587
-12,897
-27% -$747K 0.82% 37
2025
Q4
$2M Sell
48,484
-5,741
-11% -$223K 0.51% 52
2025
Q3
$2.13M Buy
54,225
+38,364
+242% +$980K 0.52% 58
2025
Q2
$295K Sell
15,861
-15,526
-49% -$291K 0.11% 138
2025
Q1
$569K Hold
31,387
– – 0.22% 121
2024
Q4
$684K Buy
31,387
+11,579
+58% +$298K 0.25% 116
2024
Q3
$542K Buy
+19,808
New +$552K 0.19% 124

Other funds holding DNTH

HighVista Strategies's DNTH Position: Q3 2026 in Review

HighVista Strategies reduced its Dianthus Therapeutics (DNTH) stake by 36% in Q3 2026, selling an estimated $1.94M and leaving 32,480 shares worth $2.86M. The position accounts for 0.75% of the portfolio, ranked #39.

HighVista Strategies first reported a position in DNTH in Q3 2024 and has held it in 9 quarters since. The position peaked at $4.98M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • HighVista Strategies held 32,480 shares of Dianthus Therapeutics worth $2.86M as of Q3 2026.
  • HighVista Strategies sold 18,645 Dianthus Therapeutics shares in Q3 2026, an estimated $1.94M.
  • Dianthus Therapeutics made up 0.75% of HighVista Strategies's portfolio in Q3 2026, its #39 holding.
  • HighVista Strategies first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • HighVista Strategies's Dianthus Therapeutics position peaked at $4.98M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on HighVista Strategies's 13F filing for Q3 2026, filed 13 Nov 2026.